These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36883059)

  • 41. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma.
    Song G; Shi Y; Meng L; Ma J; Huang S; Zhang J; Wu Y; Li J; Lin Y; Yang S; Rao D; Cheng Y; Lin J; Ji S; Liu Y; Jiang S; Wang X; Zhang S; Ke A; Wang X; Cao Y; Ji Y; Zhou J; Fan J; Zhang X; Xi R; Gao Q
    Nat Commun; 2022 Mar; 13(1):1642. PubMed ID: 35347134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma.
    Kida A; Mizukoshi E; Kitahara M; Miyashita T; Goto S; Kamigaki T; Takimoto R; Asai J; Kakinoki K; Urabe T; Tomita K; Kaneko S
    Int J Cancer; 2024 Feb; 154(4):738-747. PubMed ID: 37676069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular profiling reveals potential targets in cholangiocarcinoma.
    Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK
    World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma.
    Sang C; Yan L; Lin J; Lin Y; Gao Q; Shen X
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):199. PubMed ID: 38627278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
    Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
    Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
    Xu L; Wang P; Zhang W; Li W; Liu T; Che X
    Front Oncol; 2021; 11():757498. PubMed ID: 34660327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Establishment and validation of lncRNA-related prognostic signatures in cholangiocarcinoma.
    Li F; Zhang J; Zhang J; Xue H; Liu L; Yang Z; Dong H; Wang K
    Genomics; 2023 May; 115(3):110621. PubMed ID: 37068643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
    Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
    PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncostatin M expression and
    Liu Q; Lan T; Song Y; Cai J; Yu X; Chen W
    Aging (Albany NY); 2020 Nov; 12(21):21518-21543. PubMed ID: 33216732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
    Lurje G; Bednarsch J; Czigany Z; Lurje I; Schlebusch IK; Boecker J; Meister FA; Tacke F; Roderburg C; Den Dulk M; Gaisa NT; Bruners P; Neumann UP
    Eur J Surg Oncol; 2019 Aug; 45(8):1468-1478. PubMed ID: 31053477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expressional and prognostic value of HPCAL1 in cholangiocarcinoma via integrated bioinformatics analyses and experiments.
    Ma M; Zeng G; Li J; Liang J; Huang L; Chen J; Lai J
    Cancer Med; 2023 Jan; 12(1):824-836. PubMed ID: 35645147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
    Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
    Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alteration of STK11 Expression Associated With Cholangiocarcinoma Progression.
    Sirithawat P; Jusakul A; Kongpetch S; Thanee M; Srichanchara P; Panjaroensak S; Kimawaha P; Janthamala S; Aphivatanasiri C; Techasen A
    In Vivo; 2023; 37(4):1638-1648. PubMed ID: 37369462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.
    Wongjarupong N; Assavapongpaiboon B; Susantitaphong P; Cheungpasitporn W; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
    BMC Gastroenterol; 2017 Dec; 17(1):149. PubMed ID: 29216833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification.
    Tawarungruang C; Khuntikeo N; Chamadol N; Laopaiboon V; Thuanman J; Thinkhamrop K; Kelly M; Thinkhamrop B
    BMC Cancer; 2021 May; 21(1):497. PubMed ID: 33941120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion.
    Zhou Z; Ma J
    Cancer Biomark; 2019; 24(2):173-181. PubMed ID: 30594918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
    Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.